In a turbulent market environment, Cytokinetics , Incorporated (NASDAQ:CYTK) stock has reached its 52-week low, trading at $41.69, with a sharp 14% decline just last week. According to InvestingPro ...

SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), currently valued at approximately $5 billion in market capitalization, has announced the appointment of Robert E. Landry to its Board ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

Cytokinetics (CYTK) announced the appointment of Robert Landry to its Board of Directors. Mr. Landry brings over three decades of financial and ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had ...

Inspire Investing LLC boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.